Advancing Precision Therapeutics in Older Adults: A Scoping Review of Pharmacogenomic Service Models
Gene–drug pair / mechanism
Design elements of pharmacogenomic services embedded in medication management programmes for older adults
Summary
Older adults combine polypharmacy, age-related pharmacokinetic and pharmacodynamic variability and medication-related harm, and implementing pharmacogenomics in this population meets specific challenges. This scoping review, conducted according to PRISMA across five databases up to May 2026, describes pharmacogenomic testing services used to inform prescribing in adults aged 65 and over. Eleven services were identified, in primary care, geriatric clinics, residential aged care, pharmacies and telepharmacy. Seven design elements emerge, including integration into medication management workflows, pre-implementation professional education, population-relevant panels, decision-support tools for drug-gene interactions and pharmacist-led interpretation. Most services are embedded in broader medication management programmes: testing refines therapeutic decision making rather than replacing it.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
The useful message is that, in older adults, pharmacogenomics works as a refinement of existing medication management, not as a separate pathway. The eleven services described are heterogeneous and the abstract reports no clinical outcome: the seven-element framework is a design basis to be tested, not evidence of efficacy. Useful for an implementation project, with no recommendation value.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 1/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 6/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime